Recent Updates
Recently added Catalysts
IMNM Positive Sentiment

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wednesday, September 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunome, Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference scheduled for September 14, 2026. The presentation will be made by the company's management at 11:00 a.m. ET. Interested investors can access the live audio webcast through the company's website.
Price reaction · baseline $27.065 (2026-09-01 close) · hit pre-market · clean, no other IMNM news in the window
day 0 close
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunome is actively participating in a significant investment conference.
  • The company is focused on developing innovative cancer therapies.
  • The presentation provides an opportunity for investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
1.9%
average across 2 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
177Lu-3050
Phase 1 · Solid Malignancies

Full Press Release Details

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company’s website at www.immunome.com.

Frequently Asked Questions

When will Immunome present at the conference?

Immunome will present at the H.C. Wainwright conference on September 14, 2026.

How can I access the presentation?

The presentation can be accessed via a live audio webcast on Immunome's website.

What is the focus of Immunome's therapies?

Immunome focuses on developing targeted cancer therapies.

What time is Immunome's presentation scheduled?

The presentation is scheduled for 11:00 a.m. ET.

ShareAdd on Google
Tags: IMNM Viatris Investor Conferences Healthcare Immunome H.C. Wainwright investment conference cancer therapies clinical-stage oncology
Last updated: Sep 2, 2026

Biotech snapshot

Cash runway
$520M liquidity · $21M/mo burn
~25 mo
Minimal dilution risk
Lead asset
177Lu-3050Phase 1
Solid Malignancies →

Catalyst track record

+56%
best trade around IMNM's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for IMNM.

See every catalyst's timing & PoA →